PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.31%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-49.44%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
3.87%
Other expenses growth less than half of TRVN's 106.57%. David Dodd would verify if advantage is sustainable.
-37.34%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-37.34%
Both companies reducing total costs. Martin Whitman would check industry trends.
-62.14%
Both companies reducing interest expense. Martin Whitman would check industry trends.
3.87%
D&A growth while TRVN reduces D&A. John Neff would investigate differences.
47.24%
EBITDA growth exceeding 1.5x TRVN's 7.92%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
37.34%
Operating income growth exceeding 1.5x TRVN's 8.28%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
1271.24%
Other expenses growth while TRVN reduces costs. John Neff would investigate differences.
47.13%
Pre-tax income growth exceeding 1.5x TRVN's 7.84%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-62.14%
Tax expense reduction while TRVN shows 240.51% growth. Joel Greenblatt would examine advantage.
47.13%
Net income growth exceeding 1.5x TRVN's 7.84%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
50.90%
EPS growth exceeding 1.5x TRVN's 15.01%. David Dodd would verify competitive advantages.
52.86%
Diluted EPS growth exceeding 1.5x TRVN's 15.01%. David Dodd would verify competitive advantages.
7.67%
Share count reduction below 50% of TRVN's 8.34%. Michael Burry would check for concerns.
12.32%
Diluted share reduction below 50% of TRVN's 8.34%. Michael Burry would check for concerns.